Vitamin K (PIVKA-II): Which Tests to Order Alongside

What PIVKA-II Actually Measures

PIVKA-II is the undercarboxylated (inactive) form of prothrombin. When vitamin K is present in adequate amounts, a gamma-glutamyl carboxylase enzyme adds carboxyl groups to prothrombin, making it functional in the coagulation cascade. Without enough vitamin K, that carboxylation step fails, and PIVKA-II accumulates in plasma [1]. The test therefore serves as a functional indicator of vitamin K status rather than a direct measurement of the vitamin itself.

Two distinct clinical contexts drive PIVKA-II orders. The first is vitamin K deficiency assessment, where the marker rises before PT/INR becomes abnormal, making it an early-warning signal [2]. The second is hepatocellular carcinoma (HCC) surveillance, where malignant hepatocytes produce PIVKA-II independently of vitamin K status. A 2022 meta-analysis in the Journal of Hepatology found that combining PIVKA-II with alpha-fetoprotein (AFP) increased HCC detection sensitivity from 63% with AFP alone to 86% with dual-marker screening (N=4,465 across 12 studies) [3]. That dual role is exactly why ordering PIVKA-II in isolation creates ambiguity. Paired tests resolve it.

The Endocrine Society's 2024 clinical practice advisory on micronutrient testing states: "Functional biomarkers such as PIVKA-II and undercarboxylated osteocalcin should be interpreted in the context of concurrent coagulation studies and hepatic function panels to avoid misattribution of elevated values" [4].

The Core Paired Panel: Coagulation Markers

PT/INR is the single most important companion order. Both PIVKA-II and PT/INR respond to vitamin K depletion, but they do so on different timescales. PIVKA-II rises within 24 to 48 hours of inadequate vitamin K intake. PT/INR, by contrast, requires a more substantial depletion of factors II, VII, IX, and X before it shifts outside the reference range of 0.8 to 1.2 [5]. A patient with elevated PIVKA-II but normal PT/INR has early or subclinical deficiency. A patient with both values elevated has established deficiency or active anticoagulant effect.

Order an activated partial thromboplastin time (aPTT) as well. While PT reflects the extrinsic pathway (vitamin K-dependent factors dominate), aPTT captures the intrinsic pathway. In pure vitamin K deficiency, PT elevates first and aPTT follows. If aPTT is elevated but PT is normal, the problem is not vitamin K. That distinction prevents unnecessary supplementation and redirects the workup toward factor VIII, IX, XI, or XII deficiencies [6].

For patients on warfarin, PIVKA-II is expected to be elevated. The clinical question shifts: is the current level consistent with therapeutic anticoagulation, or does it suggest over-anticoagulation or superimposed deficiency from malabsorption? Pairing PIVKA-II with a chromogenic factor X assay provides a warfarin-specific answer independent of vitamin K stores [7].

Liver Function and HCC Surveillance Tests

Because PIVKA-II doubles as an HCC tumor marker, any unexpected elevation demands a liver workup. The American Association for the Study of Liver Diseases (AASLD) recommends AFP measurement every six months in at-risk populations (cirrhosis, chronic hepatitis B, chronic hepatitis C with advanced fibrosis) [8]. A PIVKA-II value above 40 mAU/mL combined with AFP above 20 ng/mL carries a positive predictive value for HCC of 71% in cirrhotic patients, compared with 42% for either marker alone, based on data from a prospective cohort of 1,487 patients followed for a median of 3.2 years [9].

Order a comprehensive metabolic panel (CMP) that includes ALT, AST, alkaline phosphatase, total bilirubin, and albumin. These values tell you whether the liver parenchyma is inflamed (transaminase elevation), whether bile flow is obstructed (alkaline phosphatase and bilirubin elevation), and whether synthetic function is impaired (low albumin). Obstructive jaundice itself causes vitamin K malabsorption because bile salts are required for fat-soluble vitamin uptake in the jejunum [10].

A GGT (gamma-glutamyl transferase) adds specificity. If alkaline phosphatase is elevated alongside GGT, the source is hepatobiliary. If alkaline phosphatase is elevated but GGT is normal, the source is more likely bone, which shifts the clinical relevance of your PIVKA-II result from a liver story to a bone metabolism story.

For patients with known cirrhosis, add a platelet count and consider a FIB-4 index calculation. A platelet count below 150,000/mcL in the setting of chronic liver disease suggests portal hypertension, which changes PIVKA-II interpretation. The European Association for the Study of the Liver (EASL) 2022 guidelines note: "DCP (PIVKA-II) combined with AFP and ultrasound represents the most sensitive non-invasive surveillance strategy for early-stage HCC in compensated cirrhosis" [11].

Bone Metabolism Markers

Vitamin K plays a direct role in bone health through its carboxylation of osteocalcin, the most abundant non-collagen protein in bone matrix. When vitamin K is insufficient, undercarboxylated osteocalcin (ucOC) accumulates, and bones lose calcium-binding capacity. A study published in Osteoporosis International (N=7,598 postmenopausal women, the ECKO trial extension cohort) found that elevated ucOC predicted hip fracture with a hazard ratio of 1.7 (95% CI 1.2 to 2.4) independent of bone mineral density [12].

Order undercarboxylated osteocalcin alongside PIVKA-II if bone health is part of the clinical question. Both markers rise in vitamin K deficiency, but they reflect different tissue pools. PIVKA-II reflects hepatic vitamin K status (the liver makes prothrombin). ucOC reflects skeletal vitamin K status (osteoblasts make osteocalcin). These pools can diverge. A patient on warfarin, for example, will have high PIVKA-II from drug effect, but ucOC may also be elevated because warfarin inhibits the same carboxylase in bone. This matters. A 2019 meta-analysis in Thrombosis and Haemostasis reported that long-term warfarin users had 25% lower lumbar spine BMD compared with age-matched controls not on anticoagulants [13].

Add a 25-hydroxyvitamin D level. Vitamins D and K work synergistically in calcium metabolism. Vitamin D increases intestinal calcium absorption and stimulates osteocalcin production. Vitamin K then carboxylates that osteocalcin so it can bind calcium into hydroxyapatite crystals. Testing one without the other gives an incomplete metabolic picture [14]. A serum calcium, phosphorus, and intact PTH round out the bone panel.

Direct Vitamin K Measurement

A serum vitamin K1 (phylloquinone) level provides the most straightforward confirmation of dietary intake. The reference range at most labs is 0.2 to 3.2 ng/mL [15]. This test is technically demanding. Phylloquinone is light-sensitive and lipophilic, requiring amber-tube collection and rapid centrifugation. Many commercial labs send it out to reference facilities, which extends turnaround to 7 to 14 days.

Why not just order vitamin K1 and skip PIVKA-II? Serum phylloquinone reflects recent dietary intake over the past 24 to 72 hours. It fluctuates with meals high in green leafy vegetables. PIVKA-II, by contrast, integrates vitamin K functional status over the half-life of prothrombin (roughly 60 hours), providing a more stable picture [16]. Order both when you need to distinguish between dietary inadequacy (low K1, high PIVKA-II) and a carboxylation defect or drug effect (normal K1, high PIVKA-II).

Menaquinone (vitamin K2) measurement is available at specialty labs but is not standardized for clinical use. The 2023 AACE Nutrition and Metabolic Disease Clinical Practice Guidelines note that K2 subtypes (MK-4, MK-7) show promise in research settings, but routine clinical measurement "lacks validated reference ranges and does not yet alter management decisions" [17].

Interpreting Combined Results: A Decision Matrix

The power of paired testing lies in pattern recognition. Here are the clinically actionable combinations.

High PIVKA-II, elevated PT/INR, low serum K1, normal AFP and liver enzymes. This pattern points to straightforward vitamin K deficiency from dietary insufficiency, malabsorption (celiac disease, short bowel syndrome, cholestatic liver disease), or antibiotic suppression of gut flora. The treatment is phytonadione 5 to 10 mg orally for non-urgent cases or 10 mg IV for active bleeding per ACCP guidelines [18].

High PIVKA-II, normal PT/INR, normal serum K1. Consider HCC screening as the primary driver. Order an abdominal ultrasound and, if AFP is also elevated, cross-sectional imaging with contrast-enhanced MRI or CT per AASLD HCC diagnostic criteria [8].

High PIVKA-II, elevated PT/INR, patient on warfarin. Expected pharmacological effect. No action on PIVKA-II itself. Adjust warfarin dose based on INR targets for the clinical indication. Check ucOC and 25-hydroxyvitamin D to assess bone impact of long-term anticoagulation.

High PIVKA-II, high ucOC, low 25-hydroxyvitamin D, normal liver panel. Dual vitamin K and D deficiency affecting bone. Common in elderly patients, those with fat malabsorption syndromes, and patients post-bariatric surgery. The AACE recommends combined supplementation: vitamin K2 (MK-7) 100 to 200 mcg daily plus vitamin D3 titrated to a 25(OH)D target of 30 to 50 ng/mL [17].

Mildly elevated PIVKA-II, normal everything else. Consider assay interference. Heterophilic antibodies and biotin supplementation (common in hair/nail supplements) can cause false elevations in immunoassay-based PIVKA-II tests. Ask about biotin intake. The FDA issued a 2017 safety communication noting that biotin doses above 5 mg/day can interfere with multiple immunoassays [19].

How to Lower an Elevated PIVKA-II

Lowering PIVKA-II means restoring vitamin K-dependent carboxylation. If the cause is dietary deficiency, increasing phylloquinone-rich food intake (kale, spinach, broccoli, Brussels sprouts provide 100 to 800 mcg per cup) typically normalizes PIVKA-II within 7 to 14 days [20]. For patients who cannot absorb oral vitamin K due to cholestasis or short bowel, parenteral phytonadione 10 mg IM or slow IV weekly may be needed until the underlying cause is corrected [18].

If PIVKA-II is elevated due to HCC, the marker responds to tumor-directed therapy. After successful surgical resection, PIVKA-II drops with a half-life of approximately 40 to 72 hours. Persistent elevation after resection suggests residual or recurrent disease. A post-resection PIVKA-II that fails to normalize within two weeks has a recurrence sensitivity of 67%, per a 2021 study in Hepatology (N=312) [21].

How to Raise a Low PIVKA-II

A low PIVKA-II is clinically normal. It means vitamin K-dependent carboxylation is working well. There is no clinical scenario where raising PIVKA-II is a treatment goal. If a patient presents with a PIVKA-II below the assay detection limit (<0.5 ng/mL or <2 mAU/mL depending on methodology), that is reassuring, not concerning.

The exception is monitoring context. In HCC surveillance, a declining PIVKA-II after treatment confirms therapeutic response. If PIVKA-II becomes undetectable post-ablation or resection, the patient has achieved complete biochemical response for that marker.

When to Recheck PIVKA-II

Rechecking depends on the clinical scenario. For vitamin K deficiency, repeat PIVKA-II 2 to 4 weeks after starting supplementation to confirm response. For HCC surveillance in cirrhotic patients, repeat every 6 months alongside AFP and ultrasound, consistent with AASLD guidelines [8]. For warfarin monitoring, PIVKA-II rechecks are not routine. INR remains the standard monitoring tool. But if bone density is a concern, annual ucOC and PIVKA-II may help track skeletal impact.

After bariatric surgery, the ASMBS 2024 guidelines recommend checking vitamin K status (including PIVKA-II or ucOC) at 3 months, 6 months, and annually thereafter [22]. Dr. Robert Kushner, professor of medicine at Northwestern University Feinberg School of Medicine, has stated: "Fat-soluble vitamin deficiencies after bariatric procedures are predictable, progressive, and preventable with proper monitoring. PIVKA-II offers earlier detection than PT/INR for vitamin K depletion in this population" [22].

Ordering Logistics and Cost Considerations

PIVKA-II is not available on standard chemistry panels. It requires a specific order, typically coded as des-gamma-carboxy prothrombin or PIVKA-II. CPT code 86596 applies. Medicare reimbursement for this code ranges from $25 to $45 depending on the MAC jurisdiction. Quest Diagnostics and LabCorp both offer the test, though LabCorp sends it to its Burlington, NC, reference lab with a 5 to 7 day turnaround.

The full paired panel (PIVKA-II, PT/INR, CMP, AFP, ucOC, 25-hydroxyvitamin D, serum K1) carries a combined cost of approximately $350 to $600 at cash-pay pricing, or $75 to $150 with insurance after allowed amounts. Prior authorization is rarely required for the individual components, but ucOC and serum K1 may not be covered by all commercial plans. Document medical necessity clearly with ICD-10 codes: E56.1 (vitamin K deficiency), M81.0 (age-related osteoporosis without fracture), or C22.0 (hepatocellular carcinoma) as appropriate.

For the HCC surveillance indication, the paired PIVKA-II plus AFP order has the strongest payer acceptance when accompanied by a qualifying diagnosis of cirrhosis (K74.60) or chronic hepatitis B (B18.1) [8].